BackAthira Pharma Overview

Athira Pharma Minority Interest

Athira Pharma's minority interest is $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Athira Pharma Minority Interest History

Loading

Athira Pharma vs. peers: Minority Interest Comparison

Loading

Athira Pharma Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Athira Pharma (ATHA) FAQ

As of the most recent data (June 2026), ATHA shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ATHA's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Athira Pharma is outperforming or lagging.

Tracking ATHA's minority interest over time shows whether Athira Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has Athira Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.

Athira Pharma's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.